Earnings Insights
AI-generated analysis of quarterly earnings, concall highlights, and financial performance across Indian listed companies.
How to use these insights
Each article is built from earnings call transcripts and structured rank signals. Start with the latest summary, then open the stock page for the full company view, the concall page for quarter-by-quarter commentary, and the rankings dashboard to compare peers.
ASM Technologies Q2 FY23 earnings call: Revenue & Margins | Arthneeti
Q2 FY23
Year-on-Year Growth:** 35.3% (Q2FY23 vs Q2FY22) . Key concall takeaways from ASM Technologies Ltd's Q2 FY23 earnings call — and how it ranks against sector…
25 Sept 2026
ASM Technologies Q3 FY23 earnings call: Revenue & Margins | Arthneeti
Q3 FY23
Year-on-Year Growth:** Approximately 13.7% increase in consolidated quarterly revenue. Key concall takeaways from ASM Technologies Ltd's Q3 FY23 earnings call…
25 Sept 2026
ASM Technologies Q2 FY24 earnings call: Revenue & Margins | Arthneeti
Q2 FY24
EBITDA: ₹36.55 Mn (Q2 FY23) vs ₹58.43 Mn (Q2 FY22) — decline . Key concall takeaways from ASM Technologies Ltd's Q2 FY24 earnings call — and how it ranks…
25 Sept 2026
ASM Technologies Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Q4 FY24: ₹445.92 million . Key concall takeaways from ASM Technologies Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
25 Sept 2026
ASM Technologies Q1 FY26: Revenue ₹122.9 Cr, PAT ₹15.6 Cr | Arthneeti
Q1 FY26
Revenue from Operations for Q1FY26: ₹122.9 Cr. Key concall takeaways from ASM Technologies Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
25 Sept 2026
ASM Technologies Q3 FY26: Revenue ₹116.0 Cr, PAT ₹9.3 Cr | Arthneeti
Q3 FY26
Revenue from Operations for Q3 FY26: ₹116.0 crore . Key concall takeaways from ASM Technologies Ltd's Q3 FY26 earnings call — and how it ranks against sector…
25 Sept 2026
Ircon International Q2 FY25 earnings call: Revenue & Margins | Arthneeti
Q2 FY25
Q2 FY25 Standalone Operating Revenue: INR 2,298.86 crore, down 20.28% YoY from INR 2,883.64 crore in Q2 FY24 (Page 18). Key concall takeaways from Ircon…
25 Sept 2026
Ircon International Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Consolidated Operating Revenue Q1 FY26:** INR 1,786.3 crore . Key concall takeaways from Ircon International Ltd's Q1 FY26 earnings call — and how it ranks…
24 Sept 2026
Ircon International Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
1,965.4 crore . Key concall takeaways from Ircon International Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
24 Sept 2026
Ircon International Q1 FY27: Revenue ₹1,800.3 Cr, PAT ₹163.5 Cr | Arthneeti
Q1 FY27
Standalone Operating Revenue (Q1 FY27):** ₹1,800.3 crore . Key concall takeaways from Ircon International Ltd's Q1 FY27 earnings call — and how it ranks…
24 Sept 2026
IIFL Capital Services Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Revenue for Q3FY25: ₹6,464 million, up 11% YoY (Page 20) . Key concall takeaways from IIFL Capital Services Ltd's Q3 FY25 earnings call — and how it ranks…
24 Sept 2026
IIFL Capital Services Q1 FY25 earnings call: Revenue & Margins | Arthneeti
Q1 FY25
Q1 FY25 Revenue from Operations: ₹6,399 Mn, up 56% YoY from ₹4,091 Mn in Q1 FY24 (Page 20). Key concall takeaways from IIFL Capital Services Ltd's Q1 FY25…
24 Sept 2026
IIFL Capital Services Q2 FY25 earnings call: Revenue & Margins | Arthneeti
Q2 FY25
Revenue for Q2 FY25: ₹7,037 million, up 32% YoY from ₹5,337 million in Q2 FY24 (Page 20) . Key concall takeaways from IIFL Capital Services Ltd's Q2 FY25…
24 Sept 2026
Astrazeneca Pharma India Q1 FY19: Revenue ₹584.24 Cr | Arthneeti
Q1 FY19
Total revenue for AstraZeneca Pharma India Ltd (FY 2017-2018) reported as ₹584.24 Crore (Page 8). Key concall takeaways from Astrazeneca Pharma India Ltd's Q1…
24 Sept 2026
Jubilant Pharmova Q1 FY27 earnings call: Revenue & Margins | Arthneeti
Q1 FY27
2,229 Cr., up 17% YoY (Page 97) . Key concall takeaways from Jubilant Pharmova Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
24 Sept 2026
Jubilant Pharmova Q4 FY24 earnings call: Revenue & Margins | Arthneeti
Q4 FY24
1,759 Cr, a 5% YoY increase from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.
24 Sept 2026
Jubilant Pharmova Q1 FY25 earnings call: Revenue & Margins | Arthneeti
Q1 FY25
1,746 Cr, a 9% increase YoY. Key concall takeaways from Jubilant Pharmova Ltd's Q1 FY25 earnings call — and how it ranks against sector peers.
24 Sept 2026
Jubilant Pharmova Q2 FY25 earnings call: Revenue & Margins | Arthneeti
Q2 FY25
Q2’FY25 total income grew 5% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
24 Sept 2026
Jubilant Pharmova Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
24 Sept 2026
Jubilant Pharmova Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Q2’FY26 revenue grew by 12% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
24 Sept 2026